SCHEMBL5357801

SCHEMBL5357801

O=C(O)c1ccc(NC(=S)N/N=C/c2cc(Cl)cc(Cl)c2O)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.54
MEN1 O00255 5/20 0.54
KMT2A Q03164 5/20 0.54
L3MBTL1 Q9Y468 3/20 0.54
NPC1 O15118 3/20 0.54
TDP1 Q9NUW8 2/20 0.54
USP2 O75604 1/20 0.54
MCOLN3 Q8TDD5 1/20 0.54
RAB9A P51151 2/20 0.51
LMNA P02545 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
MAPT P10636 6/20 0.49
POLB P06746 1/20 0.49
MCL1 Q07820 1/20 0.49
GAA P10253 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
ALDH1A1 P00352 3/20 0.48
PIK3CG P48736 1/20 0.48
HDAC8 Q9BY41 1/20 0.46
CYP1A2 P05177 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5357804 1.00 KDM4E (0.54) KDM4EMEN1KMT2AL3MBTL1NPC1
SCHEMBL5358196 0.88 MAPT (0.64) KDM4EMEN1KMT2AL3MBTL1NPC1
SCHEMBL5358192 0.88 MAPT (0.64) KDM4EMEN1KMT2AL3MBTL1NPC1
SCHEMBL5362925 0.84 PARP1 (0.59) KDM4EMEN1KMT2AL3MBTL1NPC1
SCHEMBL5365340 0.84 PARP1 (0.59) KDM4EMEN1KMT2AL3MBTL1NPC1
SCHEMBL5357627 0.83 KDM4E (0.59) KDM4EMEN1KMT2AL3MBTL1NPC1
SCHEMBL5362550 0.83 KDM4E (0.59) KDM4EMEN1KMT2AL3MBTL1NPC1
SCHEMBL5365029 0.80 MAPT (0.52) KDM4EMEN1KMT2AL3MBTL1NPC1
SCHEMBL5365026 0.80 MAPT (0.52) KDM4EMEN1KMT2AL3MBTL1NPC1
SCHEMBL5362822 0.80 MAPT (0.64) KDM4EMEN1KMT2AL3MBTL1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058990-A1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION 2004-03-25 US claimed
US-7241783-B2 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION (US) 2007-07-10 US disclosed
EP-1349613-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2005-09-21 EP disclosed
US-20040058990-A1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION 2004-03-25 US disclosed
EP-1349613-A2 THROMBOPOIETIN MIMETICS SmithKline Beecham Corporation (US) 2003-10-08 EP disclosed
WO-2002049413-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058990-A1 Thrombopoietin mimetics MPL, THPO, TEK KDM4E 3460/4885MEN1 481/4885KMT2A 2928/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.